In conclusion, our study not only provides valuable mechanistic insights into the role of Trem2 in regulating macrophage‐mediated inflammation and fibrosis in the AKI–CKD transition but also offers a new avenue for TREM2‐overexpressing macrophage‐based cell therapy to treat kidney diseases. The gene discussed is TREM2; the disease is acute kidney injury.